Results 151 to 160 of about 9,340 (184)

Mepolizumab Reduces Inflammatory Eosinophils in Nasal Polyp Tissue and Restores Histological Alterations.

Journal of investigational allergology & clinical immunology
BACKGROUND AND OBJECTIVES Eosinophilic inflammation and IL-5 are key therapeutic targets in type 2 chronic rhinosinusitis with nasal polyposis (CRSwNP). Based on surface expression of CD62L, 2 eosinophil subpopulations, homeostatic and inflammatory, were
A. Matucci, M. Accinno, G. Maggiore, B. Brugnoli, E. Vivarelli, L. Cosmi, P. Parronchi, M. Perlato, M. Milanese, G. Licci, O. Rossi, A. Minzoni, P. Orlando, O. Gallo, A. Palomba, C. Ammatuna, T. Tatti, A. Vultaggio   +17 more
semanticscholar   +1 more source

An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma

Expert Opinion on Biological Therapy
Introduction Clinical experience with anti-interleukin (IL)-5 biologic therapies for severe asthma has been increasing, alongside deeper and broader research focusing on the role of IL-5 and the IL-5 targeted mepolizumab.
Zheng Zhu, Xiaoying Chen, Yiting Luo, R. Feng, Zicong Zhou, Ruchong Chen   +5 more
semanticscholar   +1 more source

Mepolizumab

Reactions Weekly, 2019
  +9 more sources

Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial

Allergy Asthma and Immunology Research
Purpose Clinical remission (CR), an emerging treatment goal in asthma, was assessed by a post hoc analysis of a phase 3 study of mepolizumab in severe asthma with an eosinophilic phenotype (SA-EP). Methods Asthmatic patients aged ≥ 12 years, with a blood
Ruchong Chen, Y. Dai, Danrong Yang, Chuntao Liu, Wei Han, Wei Gu, Jie Cao, Qiong Zhou, P. Howarth, Stephen Weng, Cui Xiong, Jie Huang, Peiwen Liang, Nanshan Zhong   +13 more
semanticscholar   +1 more source

The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma

Journal of Asthma and Allergy
Purpose Mepolizumab, which causes a decrease in the number of blood eosinophils, is used to treat patients with severe eosinophilic asthma (SEA). However, there is a relative lack of data on dynamic changes in blood eosinophil subtype distribution and ...
A. Rimkunas, A. Januškevičius, E. Vasyle, J. Palacionyte, V. Kalinauskaite-Zukauske, S. Miliauskas, K. Malakauskas   +6 more
semanticscholar   +1 more source

Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis

Allergy. European Journal of Allergy and Clinical Immunology
Severe asthma with an eosinophilic phenotype (SAEP) and chronic rhinosinusitis with nasal polyps (CRSwNP) are predominantly type 2‐driven diseases, characterised by eosinophilic inflammation and substantial disease burden.
Florence Schleich, S. Loukides, Rekha Chaudhuri, J. Leuppi, E. Heffler, Cristian Domingo, C. Micheletto, Thomas Paulsson, Nina Gaw, K. Kallinikou, Carla Vossen, Florent Guelfucci, Jyothi Menon, Armel Ngami, Ines Palomares   +14 more
semanticscholar   +1 more source

Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)

Allergy Asthma and Immunology Research
Mepolizumab, an interleukin-5 antagonist, is globally recognized for its efficacy in randomized controlled trials for the treatment of severe eosinophilic asthma.
So-Young Park, Daegeun Lee, Joo-Hee Kim, Youngsoo Lee, G. Ban, D. Sim, Jae-Woo Kwon, So Ri Kim, Woo-Jung Song, Heung-Woo Park, Yoon-Seok Chang, Young-Il Koh, Byung Jae Lee, Hae-Sim Park, You Sook Cho, Sang-Heon Kim   +15 more
semanticscholar   +1 more source

Mepolizumab

Reactions Weekly, 2018
  +7 more sources

Analysis of the economically justifiable price of mepolizumab in adults with asthma in Colombia

Journal of Asthma
Introduction Asthma imposes a critical economic burden on health systems, especially with the incorporation of new drugs. Recently, mepolizumab has been approved to prevent exacerbations in patients with eosinophilic asthma, however their high cost ...
J. Buendía, Diana Guerrero-Patiño, Juan Antonio Buendia Sanchez   +2 more
semanticscholar   +1 more source

Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma

Allergy. European Journal of Allergy and Clinical Immunology
Eosinophils are key therapeutic targets in severe asthma that are suppressed by IL5 (mepolizumab) and IL5 receptor (benralizumab) blockade. The effect of IL5 pathway biologics on recently described homeostatic (hEOs) and inflammatory (iEOs) eosinophil ...
M. Fricker, J. Harrington, Sarah A. Hiles, P. Gibson   +3 more
semanticscholar   +1 more source